- Home
- HGV vs PTGX Comparison
HGV vs PTGX Comparison
Compare HGV & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGV
- PTGX
- Stock Information
- Founded
- HGV 1992
- PTGX 2006
- Country
- HGV United States
- PTGX United States
- Employees
- HGV N/A
- PTGX N/A
- Industry
- HGV Hotels/Resorts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- HGV Consumer Discretionary
- PTGX Health Care
- Exchange
- HGV Nasdaq
- PTGX Nasdaq
- Market Cap
- HGV 3.7B
- PTGX 3.3B
- IPO Year
- HGV N/A
- PTGX 2016
- Fundamental
- Price
- HGV $44.86
- PTGX $51.25
- Analyst Decision
- HGV Buy
- PTGX Strong Buy
- Analyst Count
- HGV 9
- PTGX 9
- Target Price
- HGV $46.44
- PTGX $67.11
- AVG Volume (30 Days)
- HGV 838.5K
- PTGX 1.0M
- Earning Date
- HGV 08-07-2025
- PTGX 08-05-2025
- Dividend Yield
- HGV N/A
- PTGX N/A
- EPS Growth
- HGV N/A
- PTGX N/A
- EPS
- HGV 0.34
- PTGX 0.86
- Revenue
- HGV $4,446,000,000.00
- PTGX $207,801,000.00
- Revenue This Year
- HGV $19.10
- PTGX N/A
- Revenue Next Year
- HGV $6.88
- PTGX $47.15
- P/E Ratio
- HGV $131.46
- PTGX $59.19
- Revenue Growth
- HGV 17.40
- PTGX N/A
- 52 Week Low
- HGV $30.59
- PTGX $32.50
- 52 Week High
- HGV $45.53
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- HGV 75.50
- PTGX 45.80
- Support Level
- HGV $41.22
- PTGX $49.86
- Resistance Level
- HGV $41.42
- PTGX $57.24
- Average True Range (ATR)
- HGV 1.09
- PTGX 2.06
- MACD
- HGV 0.47
- PTGX -0.78
- Stochastic Oscillator
- HGV 91.08
- PTGX 16.14
About HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.